Home
University of Bergen
Lars Bø's picture

Lars Bø

Professor
Department of Clinical Medicine
  • E-mailLars.Bo@uib.no
  • Phone+47 55 97 61 86
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. European Radiology. 3576-3587.
  • Show author(s) (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and neuroinflammation. 1-10.
  • Show author(s) (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry. 849-857.
  • Show author(s) (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 4 pages.
  • Show author(s) (2022). Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. Journal of Neurology, Neurosurgery and Psychiatry. 1-5.
  • Show author(s) (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. Multiple Sclerosis Journal, Experimental, Translational and Clinical. 1-10.
  • Show author(s) (2021). Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. Scientific Reports. 16 pages.
  • Show author(s) (2021). A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. PLOS ONE. 1-16.
  • Show author(s) (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. Multiple Sclerosis. 1-9.
  • Show author(s) (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. Journal of Neuroimmunology.
  • Show author(s) (2019). Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Research Notes. 1-5.
  • Show author(s) (2018). The economic impact of multiple sclerosis to the patients and their families in Norway. European Journal of Health Economics. 1243-1257.
  • Show author(s) (2017). Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. Journal of Neurology, Neurosurgery and Psychiatry. 621-625.
  • Show author(s) (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. European Journal of Neurology. 18-27.
  • Show author(s) (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. Neurochemistry International. 28-40.
  • Show author(s) (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Journal of Neuroimmunology. 180-186.
  • Show author(s) (2014). Employment among patients with multiple sclerosis-A population study. PLOS ONE.
  • Show author(s) (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. APMIS : Acta pathologica, microbiologica et immunologica Scandinavica. Supplementum. 1178-1186.
  • Show author(s) (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLOS ONE.
  • Show author(s) (2012). The cuprizone model: regional heterogeneity of pathology. APMIS - Journal of Pathologiy, Microbiology and Immunology. 648-657.
  • Show author(s) (2012). Poor Sleep in Patients with Multiple Sclerosis. PLOS ONE. 5 pages.
  • Show author(s) (2012). A need for national registries and international collaborative research in multiple sclerosis. Acta Neurologica Scandinavica. 1-3.
  • Show author(s) (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLOS ONE. 8 pages.
  • Show author(s) (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
  • Show author(s) (2010). Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Multiple Sclerosis. 406-411.
  • Show author(s) (2009). Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. Multiple Sclerosis. 180-188.
  • Show author(s) (2009). Spinal Cord Neuronal Pathology in Multiple Sclerosis. Brain Pathology. 642-649.
  • Show author(s) (2009). Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. Journal of Neurology, Neurosurgery and Psychiatry. 182-187.
  • Show author(s) (2009). Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. Journal of Neuropathology and Experimental Neurology. 1021-1028.
  • Show author(s) (2009). Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain. 1190-1199.
  • Show author(s) (2009). Enhanced number and activity of mitochondria in multiple sclerosis lesions. Journal of Pathology. 193-204.
  • Show author(s) (2009). Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. Experimental Neurology. 160-166.
  • Show author(s) (2009). Abundant extracellular myelin in the meninges of patients with multiple sclerosis. Neuropathology and Applied Neurobiology. 283-295.
  • Show author(s) (2009). A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. Clinical Nutrition. 83-87.
  • Show author(s) (2008). The cuprizone model for demyelination. Acta Neurologica Scandinavica. 72-76.
  • Show author(s) (2008). Mast cell transcripts are increased within and outside multiple sclerosis lesions. Journal of Neuroimmunology. 176-185.
  • Show author(s) (2008). Homogeneity of active demyelinating lesions in established multiple sclerosis. Annals of Neurology. 16-25.
  • Show author(s) (2007). The blood-brain barrier in cortical multiple sclerosis lesions. Journal of Neuropathology and Experimental Neurology. 321-328.
  • Show author(s) (2007). Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Archives of Neurology. 76-80.
  • Show author(s) (2007). Extensive hippocampal demyelination in multiple sclerosis. Journal of Neuropathology and Experimental Neurology. 819-827.
  • Show author(s) (2006). Grey matter pathology in multiple sclerosis. Acta Neurologica Scandinavica. 48-50.
  • Show author(s) (2003). Subpial demyelination in the cerebral cortex of multiple sclerosis. Journal of Neuropathology and Experimental Neurology. 723-732.
  • Show author(s) (2003). Intracortical demyelination in multiple sclerosis is not associated with increased lymphocyte infiltration. Mult Scler. 323-331.
  • Show author(s) (2002). VCAM-1-positive microglia target oligodendrycytes at the border of multiple sclerosis lesions. Journal of Neuropathology and Experimental Neurology. 539-546.
  • Show author(s) (2002). Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with co-stimulatory molecules. Journal of Neuroimmunology. 82-89.
  • Show author(s) (2001). Transected Neurites, Apoptotic Neurons and Reduced Inflammation in Cortical MS Lesions. Annals of Neurology. 389-400.
  • Show author(s) (1999). Pathogenesis of tissue injury in MS lesions. Neuroimmunomodulation. 49-56.
Popular scientific lecture
  • Show author(s) (2001). Multippel sklerose: sykdomsmekanismer.
Academic lecture
  • Show author(s) (2002). Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with co-stimulatory molecules.
  • Show author(s) (2001). Normal appearing cortical tissue, pathology studies.
  • Show author(s) (2001). Differences in pathology between secondary and primary multiple sclerosis.
Reader opinion piece
  • Show author(s) (2014). Re: Uetisk av nevrologene ikke å tilby pasienter med multippel sklerose cytostatikabehandling med autolog stamcellestøtte. Tidsskrift for Den norske legeforening. 2239-2240.
Short communication
  • Show author(s) (2016). Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. Headache. 1035-1039.
Feature article
  • Show author(s) (2022). Amming og behandling av multippel sklerose. Tidsskrift for Den norske legeforening. 1-5.
Doctoral dissertation
  • Show author(s) (2017). Patient-centered outcomes in multiple sclerosis. Results from observational studies on sleep, employment and survival.
  • Show author(s) (1998). Multiple sclerosis, immunopathological studies of inflammatory control nervous system demyelination. -.
Academic chapter/article/Conference paper
  • Show author(s) (2014). Multippel Sklerose. 10 pages.
Abstract
  • Show author(s) (2012). Poor sleep in patients with multiple sclerosis. European Journal of Neurology. 706-706.
  • Show author(s) (2009). MITOCHONDRIAL ALTERATIONS IN ASTROCYTES IN MS LESIONS. Glia. S134-S134.
  • Show author(s) (2009). Histopathological characterisation of the cuprizone model for demyelination. Multiple Sclerosis. S177-S177.
  • Show author(s) (2009). Equal loss of corticospinal axons despite less demyelination in primary vs secondary progressive multiple sclerosis. Neuropathology and Applied Neurobiology. 17-18.
  • Show author(s) (2008). Meningeal inflammation in multiple sclerosis. Multiple Sclerosis. S273-S274.
  • Show author(s) (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. Multiple Sclerosis. S90-S91.
  • Show author(s) (2008). Extensive myelin deposition in the meninges of patients with multiple sclerosis. Multiple Sclerosis. S273-S273.
  • Show author(s) (2008). A homogeneous pattern of active demyelination in patients with established multiple sclerosis. Journal of Neuroimmunology. 264-265.
Poster
  • Show author(s) (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis.
  • Show author(s) (2014). Magnetization transfer ratio (MTR) increased unexpectedly in EAE induced mice.
Academic literature review
  • Show author(s) (2022). Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke – A Systematic Review and Meta-Analysis. Frontiers in Neurology.
  • Show author(s) (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. Neurology. E1562-E1573.
  • Show author(s) (2019). B cell depletion in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy. 261-271.
  • Show author(s) (2015). The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurologica Scandinavica. 24-28.
  • Show author(s) (2013). Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. Acta Neurologica Scandinavica, Supplementum. 24-30.
  • Show author(s) (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. Acta Neurologica Scandinavica. 70-75.
  • Show author(s) (2009). The histopathology of grey matter demyelination in multiple sclerosis. Acta Neurologica Scandinavica. 51-57.
Article in business/trade/industry journal
  • Show author(s) (2019). Synsproblemer ved multippel sklerose. Tidsskrift for Den norske legeforening. 7 pages.

More information in national current research information system (CRIStin)